Conversations between clients and developers in medical computer vision almost always follow the same script: "You detect defects on a conveyor belt. There, it’s a part and a crack; here, it’s an image and a tumor. Give us 99% accuracy just to be safe." Architecturally, there is no chasm between a weld seam defect and a lung nodule—the same families of neural networks handle both. But the moment the word "accuracy" is uttered, the project enters a zone of financial turbulence. The mathematics of screening is unforgiving: on a sample where disease prevalence is below 1%, a model that blindly outputs "normal" will boast 99.2% accuracy. It won't find a single tumor, but it will look fantastic in reports.
In industrial CV, defects occur in roughly 20% of cases, making metrics behave predictably. In medicine, however, we are fighting extremely unbalanced data. The MASAI study (published in The Lancet, January 29, 2026) serves as a cold shower for optimists: out of 53,043 participants, cancer was detected in only 420. That is just 0.79% of the sample. In these conditions, traditional accuracy becomes a measure of disease prevalence rather than algorithmic quality.
The Economics of a False Alarm
When a CEO demands 98.5% specificity, they view it as a synonym for reliability. But let’s translate those percentages into real people. Using the MASAI case, a 1.5% false positive rate across a group of 52,600 healthy women means 790 patients are called back for follow-up exams unnecessarily. Meanwhile, there were only 338 actually ill patients in the entire group.
Out of 1,130 recalls, only 30% were justified. For every tumor found, two healthy women are sent into the psychological hell of waiting for a diagnosis.
This is Positive Predictive Value (PPV)—the metric that truly dictates the business workload. In the German PRAIM study (Nature Medicine), PPV stood at 17.9% with AI versus 14.9% in the control group. Cancer was confirmed in only one out of every six patients called back. In medical terms, this is a success; for unit economics, it means the AI isn't saving resources, but rather multiplying the load on expensive equipment and verifying physicians.
The Price of the Extra Nine
The technological illusion lies in the belief that specificity can be infinitely fine-tuned through thresholds. To raise PPV from 30% to 86%, the number of false positives must drop fifteen-fold. Yet every subsequent decimal point costs an order of magnitude more than the last. As you crank up the threshold, specificity rises, but model sensitivity inevitably sags. In MASAI, this is clearly visible in interval cancers (those appearing between screenings): 1.55 versus 1.76 per 1,000.
Any attempt to make a model "budget-friendly" by tightening thresholds causes it to miss actual pathologies. Ultimately, the true Total Cost of Ownership (TCO) includes not just software licenses, but weeks of diagnostic labor, histology for healthy individuals, and equipment depreciation. If a project’s technical specs boast "99% accuracy" without anchoring it to sensitivity on a specific stream, the product's mathematics were never calculated. Investors should take note: the medical AI bubble bursts the moment a clinic realizes that instead of downsizing, it needs to hire three more doctors just to sift through algorithmic hallucinations.